Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
Identifieur interne : 004917 ( Main/Exploration ); précédent : 004916; suivant : 004918Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
Auteurs : J C Delumeau [France] ; D. Bentué-Ferrer ; J M Gandon ; R. Amrein ; S. Belliard ; H. AllainSource :
- Journal of neural transmission. Supplementum [ 0303-6995 ] ; 1994.
English descriptors
- KwdEn :
- MESH :
- chemical , metabolism : Monoamine Oxidase.
- drug effects : Cognition.
- drug therapy : Alzheimer Disease, Parkinson Disease.
- metabolism : Brain.
- psychology : Alzheimer Disease, Parkinson Disease.
- chemical , therapeutic use : Monoamine Oxidase Inhibitors.
- Animals, Humans.
Abstract
Recent data obtained in animals and in humans suggest that both MAO-A and MAO-B inhibitors present cognitive enhancing properties of possible interest in the treatment of cognitive disorders. In addition, the rational for using selegiline as a neuroprotector in Parkinson's disease may also be applicable in Alzheimer's disease in which a dramatic increase in the MAO-B activity has been reported. It seems then worthwhile to investigate the neuroprotective effect of MAOIs in humans and to assess, furthermore, the real therapeutical benefit of their cognitive enhancing properties.
PubMed: 7931235
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001693
- to stream PubMed, to step Curation: 001652
- to stream PubMed, to step Checkpoint: 001652
- to stream Ncbi, to step Merge: 001D01
- to stream Ncbi, to step Curation: 001D01
- to stream Ncbi, to step Checkpoint: 001D01
- to stream Main, to step Merge: 005254
- to stream Main, to step Curation: 004917
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.</title><author><name sortKey="Delumeau, J C" sort="Delumeau, J C" uniqKey="Delumeau J" first="J C" last="Delumeau">J C Delumeau</name><affiliation wicri:level="3"><nlm:affiliation>Laboratory of Experimental and Clinical Pharmacology, University Hospital, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Experimental and Clinical Pharmacology, University Hospital, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D" last="Bentué-Ferrer">D. Bentué-Ferrer</name></author><author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J M" last="Gandon">J M Gandon</name></author><author><name sortKey="Amrein, R" sort="Amrein, R" uniqKey="Amrein R" first="R" last="Amrein">R. Amrein</name></author><author><name sortKey="Belliard, S" sort="Belliard, S" uniqKey="Belliard S" first="S" last="Belliard">S. Belliard</name></author><author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7931235</idno><idno type="pmid">7931235</idno><idno type="wicri:Area/PubMed/Corpus">001693</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001693</idno><idno type="wicri:Area/PubMed/Curation">001652</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001652</idno><idno type="wicri:Area/PubMed/Checkpoint">001652</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001652</idno><idno type="wicri:Area/Ncbi/Merge">001D01</idno><idno type="wicri:Area/Ncbi/Curation">001D01</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D01</idno><idno type="wicri:doubleKey">0303-6995:1994:Delumeau J:monoamine:oxidase:inhibitors</idno><idno type="wicri:Area/Main/Merge">005254</idno><idno type="wicri:Area/Main/Curation">004917</idno><idno type="wicri:Area/Main/Exploration">004917</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.</title><author><name sortKey="Delumeau, J C" sort="Delumeau, J C" uniqKey="Delumeau J" first="J C" last="Delumeau">J C Delumeau</name><affiliation wicri:level="3"><nlm:affiliation>Laboratory of Experimental and Clinical Pharmacology, University Hospital, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Experimental and Clinical Pharmacology, University Hospital, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D" last="Bentué-Ferrer">D. Bentué-Ferrer</name></author><author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J M" last="Gandon">J M Gandon</name></author><author><name sortKey="Amrein, R" sort="Amrein, R" uniqKey="Amrein R" first="R" last="Amrein">R. Amrein</name></author><author><name sortKey="Belliard, S" sort="Belliard, S" uniqKey="Belliard S" first="S" last="Belliard">S. Belliard</name></author><author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name></author></analytic><series><title level="j">Journal of neural transmission. Supplementum</title><idno type="ISSN">0303-6995</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (drug therapy)</term><term>Alzheimer Disease (psychology)</term><term>Animals</term><term>Brain (metabolism)</term><term>Cognition (drug effects)</term><term>Humans</term><term>Monoamine Oxidase (metabolism)</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Monoamine Oxidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cognition</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Alzheimer Disease</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Alzheimer Disease</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent data obtained in animals and in humans suggest that both MAO-A and MAO-B inhibitors present cognitive enhancing properties of possible interest in the treatment of cognitive disorders. In addition, the rational for using selegiline as a neuroprotector in Parkinson's disease may also be applicable in Alzheimer's disease in which a dramatic increase in the MAO-B activity has been reported. It seems then worthwhile to investigate the neuroprotective effect of MAOIs in humans and to assess, furthermore, the real therapeutical benefit of their cognitive enhancing properties.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Région Bretagne</li></region><settlement><li>Rennes</li></settlement></list><tree><noCountry><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name><name sortKey="Amrein, R" sort="Amrein, R" uniqKey="Amrein R" first="R" last="Amrein">R. Amrein</name><name sortKey="Belliard, S" sort="Belliard, S" uniqKey="Belliard S" first="S" last="Belliard">S. Belliard</name><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D" last="Bentué-Ferrer">D. Bentué-Ferrer</name><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J M" last="Gandon">J M Gandon</name></noCountry><country name="France"><region name="Région Bretagne"><name sortKey="Delumeau, J C" sort="Delumeau, J C" uniqKey="Delumeau J" first="J C" last="Delumeau">J C Delumeau</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004917 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004917 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:7931235
|texte= Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:7931235" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |